跳到正文
FDA 官方药品与生物制品信息·· 4 天前AI 评分49

FDA发布新一批产品特定指南(PSG)以促进仿制药开发,2026年共发布268份

FDA Publishes New Batch of Product-Specific Guidances to Facilitate Generic Drug Development

AI 导读

FDA发布新一批29份产品特定指南(PSG)草案,用于仿制药开发及简化新药申请(ANDA)证据生成,2026年累计发布268份。本批含15份新增、14份修订,其中11份涉及复杂产品,24份针对尚无获批ANDA的产品。

正文 · 原文

Today, the Food and Drug Administration published a new batch of draft product-specific guidances (PSGs) for developing generic drugs and generating evidence for abbreviated new drug applications (ANDAs). In total, FDA published 268 PSGs in calendar year 2026.

FDA publishes PSGs to help facilitate generic drug development, streamline ANDA assessment, and support greater access to generic drugs. Improving access to generic medicines supports the agency’s mission to advance public health, as outlined in our Drug Competition Action Plan.

This action advances the goals of the President’s Executive Order 14273, Lowering Drug Prices by Once Again Putting Americans First, accelerating the development and approval of generic drugs.

Today’s batch of 29 PSGs contains:

  • 24 for products with no approved ANDAs, including 9 for complex products
  • 15 new and 14 revised
  • 11 for complex products (4 new and 7 revised PSGs)

They address products such as:

  • Orforglipron Calcium (Foundayo, NDA 220934): The first once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist pill approved for weight management, a transformative step that lowers the access barrier for GLP-1 therapy, promoting chronic disease prevention.
  • Nerandomilast (Jascayd, NDA 218764): The first new idiopathic pulmonary fibrosis therapy approved in over a decade, a first-in-class selective phosphodiesterase-4B (PDE4B) inhibitor, distinct from existing antifibrotics.
  • Zongertinib (Hernexeos, NDA 219042): The first oral tyrosine kinase inhibitor approved as a first-line expansion treatment for HER2-mutant non-small cell lung cancer, reflecting FDA's readiness to accelerate approval pathways for targeted therapies.

This batch includes guidance that addresses products supported by GDUFA-funded research, such as:

  • Revised PSG for betaxolol hydrochloride ophthalmic drops/suspension (BETOPTIC S, NDA 019845) to add an in vitro bioequivalence option based on collaborative research involving computational modeling.
  • Revised PSG for trifarotene topical cream (AKLIEF, NDA 211527) to add an alternative characterization-based bioequivalence approach.

When finalized, the PSGs in today’s batch will describe the agency’s current thinking and recommendations on how to develop generic drug products that are therapeutically equivalent to specific reference listed drugs. FDA considers all comments to the public docket before finalizing PSGs.

Newly Updated – Upcoming PSGs

Today, FDA also updated the “Upcoming Product-Specific Guidances for Generic Drug Product Development” web page, which includes new and revised PSGs under development and includes the planned revision categories and brief descriptions of the revisions.

来源:FDA 官方药品与生物制品信息 · fda.gov